{
  "zip": "67405",
  "sector": "Healthcare",
  "fullTimeEmployees": 139,
  "longBusinessSummary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
  "city": "Illkirch-Graffenstaden",
  "phone": "33 3 88 27 91 00",
  "country": "France",
  "companyOfficers": [],
  "website": "http://www.transgene.fr",
  "maxAge": 1,
  "address1": "400 Boulevard Gonthier dâAndernach",
  "fax": "33 3 88 27 91 11",
  "industry": "Biotechnology",
  "address2": "Parc dâInnovation â CS80166 Cedex",
  "previousClose": 2.575,
  "regularMarketOpen": 2.5,
  "twoHundredDayAverage": 2.211,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 2.5,
  "navPrice": null,
  "averageDailyVolume10Day": 820,
  "totalAssets": null,
  "regularMarketPreviousClose": 2.575,
  "fiftyDayAverage": 2.211,
  "trailingAnnualDividendRate": null,
  "open": 2.5,
  "averageVolume10days": 820,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.69765,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 2.492,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 250,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 207299760,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 820,
  "priceToSalesTrailing12Months": null,
  "dayLow": 2.492,
  "ask": 0,
  "ytdReturn": null,
  "askSize": 0,
  "volume": 250,
  "fiftyTwoWeekHigh": 2.575,
  "forwardPE": -3.0390246,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 2.12,
  "bid": 0,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": 0,
  "dayHigh": 2.5,
  "exchange": "PNK",
  "shortName": "TRANSGENE",
  "longName": "Transgene SA",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "TRGNF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_386045",
  "uuid": "a4e3e150-53a6-3f5a-b524-63cdcca1982f",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": -0.40744,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": -0.82,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 83841296,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": 0.255,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.00717,
  "netIncomeToCommon": null,
  "trailingEps": -0.516,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": 9.77255,
  "heldPercentInsiders": 0.64915,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1593475200,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 29092104,
  "enterpriseValue": 208932608,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 2.5,
  "logo_url": "https://logo.clearbit.com/transgene.fr"
}